One of the possible mechanisms for resistance in ER+HER2-cancers might be due to the dysregulation of phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signalling pathway (96). This evidence concerns the gene ERBB2 and cancer.